(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
13 January 2022 (13.01.2022)

WIPO | PCT

(10) International Publication Number
WO 2022/009987 A1

(51) International Patent Classification:
C12N 15/09 (2006.01)

(21) International Application Number:
PCT/JP2021/025974

(22) International Filing Date:
09 July 2021 (09.07.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

63/049,736	09 July 2020 (09.07.2020)	US
63/212,429	18 June 2021 (18.06.2021)	US

(71) Applicant: **MODALIS THERAPEUTICS CORPORATION** [JP/JP]; 3-11-5, Nihonbashi-Honcho, Chuo-ku, Tokyo, 1030023 (JP).

(72) Inventors: **THOMPSON, Iain Robert**; c/o Modalis Therapeutics Inc., 51 Moulton Street, Cambridge, Massachusetts, 02138 (US). **YAMAGATA, Tetsuya**; c/o Modalis Therapeutics Inc., 51 Moulton Street, Cambridge, Massachusetts, 02138 (US). **AKBULUT, Talha**; c/o Modalis Therapeutics Inc., 51 Moulton Street, Cambridge, Massachusetts, 02138 (US).

(74) Agent: **TAKASHIMA, Hajime**; Meiji Yasuda Seimei Osaka Midosuji Bldg., 1-1, Fushimimachi 4-chome, Chuo-ku, Osaka-shi, Osaka, 5410044 (JP).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,

(54) Title: METHOD FOR TREATING ALZHEIMER'S DISEASE BY TARGETING MAPT GENE

[Fig. 2]



(57) Abstract: A polynucleotide, comprising the following base sequences: (a) a base sequence encoding a fusion protein of a nuclease-deficient CRISPR effector protein and a transcription repressor, and (b) a base sequence encoding a guide RNA targeting a continuous region of 18 to 24 nucleotides in length in a region set forth in SEQ ID NO: 54, 55, 56, 57, 68, 153 or 97 in the expression regulatory region of human MAPT gene. are expected to be useful for treating or preventing tauopathy including Alzheimer's disease.

WO 2022/009987 A1

[Continued on next page]

UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*
— *with sequence listing part of description (Rule 5.2(a))*